Navigation Links
The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six-Fold to Over $3.2 Billion in 2018
Date:9/15/2009

WALTHAM, Mass., Sept. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of novel therapies will drive the obesity drug market to increase more than six-fold, from $512 million in 2008 to more than $3.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Obesity finds that the high level of unmet need for efficacious and safe weight-loss therapies will propel the uptake of novel therapies and boost diagnosis and drug-treatment rates of obesity in the world's major pharmaceutical markets. According to the report, physician and patient dissatisfaction with the weight-loss efficacy of current market-leading therapies such as Roche's Xenical, GlaxoSmithKline's OTC Alli and Abbott's Meridia has created an environment that is conducive to the rapid uptake of novel agents. The most notable novel therapies that are expected to launch by 2018 include Arena Pharmaceuticals' lorcaserin and Amylin Pharmaceuticals' pramlintide/leptin combination. The combined sales of lorcaserin and pramlintide/leptin will capture 87 percent of the total obesity market in 2018, according to the report.

The report also finds that the absence of cannabinoid receptor-1 antagonists in the marketplace has created enormous opportunity for drugs with other novel mechanisms of action. Owing to safety concerns, the withdrawal of the cannabinoid-1 receptor antagonist rimonabant (Sanofi-Aventis's Acomplia) from the European markets and the compound's failure to gain U.S. regulatory approval has led several major drug companies to discontinue development of obesity drugs in this class.

"Regulatory agencies and physicians have become increasingly concerned about psychiatric side effects following rimonabant's recent withdrawal from the European market in 2008 because of - among other issues - elevated risk for depression associated with its use," said Decision Resources Therapeutic Area Director Donny Wong, Ph.D. "Previously, regulatory concern had focused on long-term cardiovascular safety following the withdrawal in 1997 of Wyeth's Redux and Pondimin due to cardiac abnormalities associated with these therapies."

The report also finds that although fixed-dose combination agents such as Vivus's Qnexa and Orexigen Therapeutics' Contrave and Empatic are generating some interest among physicians owing to their improved efficacy over currently marketed therapies, most interviewed experts remain concerned about the potential CNS side effects associated with these drugs.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
3. Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016
4. Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market
5. 2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics
6. Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
7. The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market
8. Electronic Medical Record Technology Uptake Faces Challenges
9. Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms
10. Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan
11. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Every year, thousands of dedicated Higher Education and ... annual event is coupled with a dynamic theme like Camp Canvas; this year, they’ve ... InstructureCon 0017. , To extend their partnership with Canvas beyond the LMS integration, ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... already work hand-in-hand on an Innovation Collaboration program, have signed a five-year agreement ... and cost of the care members and patients receive. The agreement also signifies ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales ... watermelon, nor would a pharmacist using that same scale to dispense medication. The first ... , These illustrations show why it is important to have the right balance ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... sleep management solution focused on delivering end-to-end sleep health care at scale, ... Recent literature shows that adherence rates for positive airway pressure (PAP) therapy, the ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Magic ... “Consumer’s Choice” Award, for favorite sex toy. Created in collaboration with website Kinkly.com, ... to be consumer voted. The Magic Wand Rechargeable won in stiff competition from ...
Breaking Medicine News(10 mins):
(Date:7/17/2017)... July 17, 2017  MedX Holdings, Inc., the manufacturer ... strengthening and rehabilitation equipment, today announced the national roll ... is considered the gold standard for the treatment of ... medical strengthening equipment. ... the physician or practice who prescribe the MedX Home ...
(Date:7/13/2017)... Mich. , July 13, 2017  Centurion Medical Products, a ... its DisImpactor ® fecal impaction removal device for hospice patient ... ... Patient pain management and ... for Hospice can help alleviate patient pain while preventing unneeded emergency ...
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
Breaking Medicine Technology: